

Tumors of Soft Tissue

Anatomy, Work-Up, and MR Features

Benjamin Levine, MD

May 14, 2009

Outline

I. Soft Tissue Anatomy

- Compartmental

I. Imaging Work-Up

- Post-Treatment Imaging


II. Soft Tissue Tumors—MR Features

- WHO Classification

Soft Tissue Anatomy

Soft Tissue

- Derived from mesenchyme:
 1. Skeletal muscle
 2. Fat
 3. Fibrous tissue
 4. Vascular structures
 5. Associated peripheral nervous system



Compartmental Anatomy

1. Local staging

- Depends on which anatomic spaces (compartments) are involved
- Intracompartmental lower stage


2. Biopsy

- Risk of seeding malignant cells along needle track
- Determines subsequent surgical approach; track usually resected

Compartmental Anatomy

- Natural Barriers define compartments:
 - Joint capsule
 - Cortex/periosteum
 - Tendon origins/insertions
 - Major fascial septae

- Extracompartmental spread by:
 - Direct tumor invasion
 - Fracture
 - Hemorrhage
 - Poorly planned biopsy



Compartmental Anatomy



General

- Skin/Subcutaneous fat
- Bone
- Paraosseous
 - Space between bone and overlying tissues
- Intraarticular
- Muscle
- Neurovascular
 - Not a compartment, but can provide route of extracompartmental spread

Compartmental Anatomy

Upper Extremity


- Upper Arm
 - Anterior
 - Posterior
- Forearm
 - Dorsal
 - Volar
- Purely Extracompartmental
 - Periclavicular
 - Axilla
 - Antecubital fossa
 - Wrist
 - Dorsum of hand



Compartmental Anatomy

Lower Extremity

- Thigh
 - Anterior
 - Posterior
 - Medial
- Lower Leg
 - Anterior
 - Deep posterior
 - Superficial posterior
 - Lateral
- Foot
 - Medial, central, lateral plantar
- Purely Extracompartmental
 - Inguinal
 - Popliteal fossa
 - Ankle
 - Dorsum of foot



Work-Up

Soft Tissue Tumors

Preliminary Evaluation

- Clinical History
 - ✓ Previous lesion/underlying malignancy?
 - ✓ Prior surgery/radiation?
 - ✓ Painful vs painless
 - ✓ Trauma
 - ✓ Anticoagulation
 - ✓ Stability over time/Variation in size

Soft Tissue Tumors

Initial Evaluation



- > 1 lesion limits DDx
- Multiple soft tissue tumors:
 - Lipomas
 - Fibromatoses
 - Neurofibromas
 - Angiomatous lesions
 - Myxomas
 - Mets (rare)



Soft Tissue Tumors

Imaging

- Radiographs (Always)
 - Specific calcifications (exostosis, phleboliths, synovial chondromatosis, myositis ossificans)
 - Non-specific calcifications (dystrophic in slow growing mass suggests synovial sarcoma)
 - Osseous Involvement



Soft Tissue Tumors

Imaging

- Sonography
 - Fast
 - Inexpensive
 - Ideal for solid vs. cystic when anatomically accessible
- CT
 - Further evaluate pattern of mineralization
 - Relationship to nearby complex osseous structures (Pelvis, shoulder, paraspinal)
- MRI
 - Modality of choice
 - Superior soft tissue contrast

Soft Tissue Tumors

Imaging

- MR cannot reliably distinguish benign from malignant soft tissue masses
- Non Specific:
 - Contrast enhancement (solid v. cystic, hematomas, necrosis for biopsy or trtmt response)
- Suggestive of malignancy:
 - Larger (5% benign tumors > 5 cm)
 - Heterogenous signal (infarction, necrosis)
 - Well-defined borders
 - Deep (1% benign tumors are deep) > superficial

Post-Treatment Imaging

Soft Tissue Tumors

Post-Treatment Imaging



- 50% patients with soft tissue sarcomas have local recurrence
- Increase Risk for Local Recurrence:
 - Tumor diagnosis
 - High Grade
 - Deep location
 - Unable to obtain wide margins
 - Radical resection vs marginal excision
 - Positive Surgical margins
- Radiation or chemotherapy (time course)
- Reconstructive surgery (time course)

Soft Tissue Tumors

Post-Treatment Imaging

- MR

- Discrete nodule (Post surgical changes more variable)
- Recurrent tumor looks like the primary tumor (review pre-op)
- Markers noting scar margins
- Contrast (necrosis/response, hematoma)





Soft Tissue Tumors

Radiation

■ Marrow changes

- As early as 8 days
- Increasing fatty signal (1-6 wks)
- Complete fatty replacement in 6-8 wks
- Can see focal non specific signal (radiation osteitis), mean 9 months




Soft Tissue Tumors


Radiation

- **Soft Tissue Changes**
(Peak 12-18 mo; half return to nl in 2-3 yrs)



- Trabecular/lattice-like subcutaneous signal
- Diffuse muscle enhancement, preservation of shape and architecture
- Signal persists in intermuscular septae longer
- Pseudotumor
- Sarcoma



T2



Post





3 yrs

Soft Tissue Tumors

Post-Treatment Changes

Chemotherapy




- May increase tumor size at first due to hemorrhage
- Necrosis predicts response



Postoperative Fluid and

Hemorrhage:



- Similar appearance seen with non-oncologic procedures
- Most seromas resolve in 3-18 months



Soft Tissue Tumors

Post-Treatment Changes




- **Reconstructive Surgery**
 - Myocutaneous flaps used in > 2/3
 - **Rotational Flaps**
 - Rotated into position preserving native neurovascular pedicle
 - **Free Flaps**
 - Completely detached with vascular pedicle reanastomosed



Soft Tissue Tumors

Reconstructive Surgery



- Atrophy with time (less with those providing function)
- Increased T2 signal initially
- Signal returns to baseline within 2 yrs (1/3 cases)
- Enhancement in 3/4; returns to baseline in 18 months in 1/3





Soft Tissue Tumors

Post-Treatment Changes

4 months





31 months







Soft Tissue Tumors

Soft Tissue Tumors

- Benign 100X more common than malignant
- Soft tissue sarcomas 2-3X more common than primary malignant bone tumors
- Tumors classified histologically based on adult tissue they resemble
- Many demonstrate specific MR features, but majority are nonspecific





Courtesy Tudor Hughes, M.D.

Soft Tissue Tumors

WHO Classification

- Neurogenic
- Vascular
- Fibroblastic
- Adipocytic
- Fibrohystiocytic
- Smooth Muscle
- Perivascular
- Skeletal Muscle
- Chondro-osseous
- Tumors of uncertain differentiation


Neurogenic Tumors

Peripheral Nerve Sheath Tumors

Benign

- Schwannomas/Neurofibromas

- Fascicular Sign
- Split Fat Sign













- Neurofibroma

- Target pattern (T2)
- Infiltrative: resection sacrifices nerve



- Schwannoma



- Eccentric
- Displaces nerve: resection spares nerve



Peripheral Nerve Sheath Tumors


Malignant

- Pain, rapid growth
- No target, split fat, or fascicular sign
- Intralesional hemorrhage and necrosis (peripheral enhancement)
- Inhomogenous (T1, T2, Post)
- Nodular
- Along course of large nerve




Peripheral Nerve Sheath Tumors

Malignant







T2




T1 Post-Gad

Malignant Peripheral Nerve Sheath Tumor?





Malignant Peripheral Nerve Sheath Tumors

- MR and CT not reliable in characterizing benign vs. malignant
- Surgical resection of entire lesion often not feasible
- Biopsy may yield false negative due to sampling error





MPNST and FDG-PET

- FDG PET sensitive (95%) in detecting MPNST in patients with NF1
- Can also detect mets or second primaries (GIST which is associated with NF1)



MPNST and PET

- PET specificity lower (72%)
- Can use 11-C Methionine PET to increase specificity (91%)



Bredella MA, et al. AJR 2007; 189:928–935

Vascular Tumors

Vascular Anomalies

Tumors of Childhood



- Hemangioma
 - *Childhood neoplasm with a proliferative and involutive phase (not applicable to any adult lesion)*

Vascular Malformations

- Capillary
- Venous
- Lymphatic
- Ateriovenous
- Mixed

Vascular Malformations

- Prevalence 1.5%
- Pelvis, extremities, intracranial most common
- Not neoplastic (do not proliferate or involute)



Vascular Malformations

Low Flow

- Venous
- Capillary
- Lymphatic



High Flow





- Arteriovenous malformation
- Arteriovenous fistula



Fayad L, et al. Vascular Malformations in the Extremities: Emphasis on MR Imaging Features that Guide Treatment Options. Skeletal Radiology 2006; 35:127-137

Low Flow Malformations

- Venous most common of the extremities
- Present at birth, grow proportionately with patient, do not regress
- Forearm flexors and quadriceps muscle most common (venous)








High Flow Malformations



- AVM

- Feeding arteries and draining veins connected by multiple dysplastic vessels



- AVF

- Direct connection between arteries and veins, bypassing capillary bed



Vascular Malformations

MR Assessment

1. Distinguish from Hemangioma

- Age + no mass effect (caution atypical low flow lesions which can appear mass-like and share features of hemangiomas, angiosarcomas, myxoid, fibrosarcoma)

2. Low vs. High Flow

- Flow voids
- Feeding arteries, draining veins, dysplastic vessels

3. Focal, multifocal, or diffuse

4. Adjacent tissue involvement

- Skin, subcutaneous, muscle, tendon, bone
- Can contain fat, hemosiderin, Ca⁺⁺, thrombus

5. Connection to normal vessels

- Arterial vs. Deep Venous (DVT risk)

Fibrous Tumors

Fibrous Tumors

I. Benign Fibrous Proliferations

- Nodular Fasciitis
- Proliferative Fasciitis
- Proliferative Myositis
- Fibroma of the Tendon Sheath
- Keloid/Hypertrophic Scar
- Elastofibroma

II. Fibromatoses

- Superficial (Palmar, Plantar, Penile)
- Deep (Intraabdominal, extraabdominal)



III. Fibrosarcomas

I. Fibrous Proliferations of Infancy/Childhood

Benign Fibroblastic Proliferations

Nodular Fasciitis





- Most common benign mesenchymal lesion histopathologically misdiagnosed as sarcoma
- 20-40 years
- < 4 cm, rapidly growing
- Upper extremity (volar forearm)



Benign Fibroblastic Proliferations

Nodular Fasciitis

- Typically subcutaneous, and attached to superficial fascia
- Low to intermediate signal on T1 and Intermediate to high signal on T2
- Enhance
- Fascial tail sign




Courtesy Tudor Hughes, M.D.


Benign Fibroblastic Proliferations

Elastofibroma

- > 55 years
- Between posterior chest wall and inferomedial scapula border (also about greater trochanter and olecranon)
- Bilateral (25%)
- Signal similar to skeletal muscle intermixed with streaky fat signal
- Heterogenous enhancement







Courtesy Tudor Hughes, M.D.



Fibromatoses

Superficial

- **Palmar Fibromatosis (Dupuytren Disease)**
 - Volar aponeurosis of hand
 - > 30 years
 - Variable T2 depends on collagen maturity and may suggest propensity to recur
- **Plantar Fibromatosis (Ledderhose Disease)**
 - Bilateral 20-50%
 - M > F (2X)
 - Associated palmar fibromatosis (10-65%)



Fibromatoses

Deep (Desmoid Tumors)

I. Intraabdominal



- FAP (Gardner Syndrome)

II. Abdominal

- Pregnant women, or OCP
- Rectus abdominis and Internal Oblique

III. Extraabdominal



- > 5 cm
- Typically solitary
- Can be aggressive, local recurrence high (87% in < 20 yo)







Deep Fibromatoses





MR Features

- Non-enhancing, T2 hypointense bands corresponding to collagen bundles (86%)
- Infiltrative border or fascial tail (80%)
- Evaluation of response to treatment:
 - Decreased cellularity and increased collagen show low T2 signal (positive response)





Courtesy Tudor Hughes, M.D.



Lipomatous Tumors

Lipomatous Tumors

Benign



- Lipoma
- Lipomatosis
- Lipomatosis of nerve
- Lipoblastoma
- Angiolipoma
- Spindle cell/Pleomorphic lipoma
- Myolipoma
- Chondroid lipoma
- Hibernoma

Malignant

- Liposarcoma
 - Well-differentiated
 - Dedifferentiated
 - Myxoid
 - Pleomorphic
 - Mixed-type

Lipoma




- Most common soft tissue tumor (50%)
- Benign neoplasm vs. local hyperplasia of fat cells
- Superficial
 - Upper back, neck, proximal extremities, abdomen
 - < 5 cm
- Deep
 - Intra vs. Intermuscular (arbitrary) (if both = *infiltrating*)





Murphey MD, et al. *Benign Musculoskeletal Lipomatous Lesions*. Radiographics 2004; 24: 1433-1466

Lipoma

- Multiple (5-15%)
- Thin, non enhancing septa (< 2 mm)
- No capsule with intramuscular and some subcutaneous lipomas
- Intramuscular lipomas have irregular margins, striated
- No malignant transformation






Lipoma



Lipomatosis of Nerve (Fibrolipomatous Hamartoma)

- < 30 years old
- Median nerve (85%)
- Macroductyly (27-67%)
(Macrodystrophia lipomatosa)
- *Lipomatosis of the nerve with or without macroductyly*








Courtesy Tudor Hughes, M.D.

Lipoblastoma



- < 3 years old
- Superficial, extremities
- Progress to mature lipomas
- Imaging appearance can be similar to myxoid liposarcoma (rare < 10 yrs old)



Soft Tissue Sarcomas





Soft Tissue Sarcomas

- 75% arise in extremities
- Usually develop de novo (not from dedifferentiation of benign tumor)
- Hematogenous metastasis (lungs)
- > 50 subtypes (75% are the following):
 - Undifferentiated Pleomorphic Sarcoma (MFH)
 - Liposarcoma
 - Leiomyosarcoma
 - Synovial Sarcoma
 - Malignant Peripheral Nerve Sheath Tumor






Undifferentiated Pleomorphic Sarcoma (MFH)

- Histologic diagnosis of exclusion
- Non specific MR features
- Peripheral enhancement common (necrosis, hemorrhage, or myxoid content)



Undifferentiated Pleomorphic Sarcoma (MFH)






Liposarcoma

- Second most common type of soft tissue sarcoma
- Five histologic subtypes:
 - Well-differentiated
 - Dedifferentiated
 - Myxoid
 - Pleomorphic
 - Mixed-type




Well-Differentiated Liposarcoma

- Most common subtype (50%)
- Deep soft tissues of extremities (65-75%), retroperitoneum (20-33%)
- No metastatic potential
- *Atypical lipomatous lesion* reserve for subcutaneous lesions






Well-Differentiated Liposarcoma

- > 75% of the lesion composed of fat
- Thick, enhancing septa (> 2mm)
- Liposarcoma > lipoma:
 - Male
 - > 66 years old
 - < 75% fatty
 - Calcifications
 - Size > 10 cm
 - Septa > 2 mm
 - Nonlipomatous nodular or globular foci





Myxoid Liposarcoma

- Second most common subtype
- Younger pt (4th-5th decade)
- *Intermuscular*, lower extremity








- Pathognomonic MR:
 - Fatty septa or nodules in a myxoid mass
 - May simulate a cyst (unusual location) or myxoma (*intramuscular*)



Leiomyosarcoma

- Smooth muscle
- Intermuscular and subcutaneous, rarely in association with a vessel (vein)
- Irregular rim enhancement
- Ca++ uncommon









Courtesy Tudor Hughes, M.D.

Synovial Sarcoma


- 2nd-4th decade
- Deep soft tissues of extremities and adjacent to joints or tendon sheaths (popliteal fossa)
- Triple T2 signal (relative to fat)
- Heterogeneous signal and variable contrast enhancement
- Ca⁺⁺ (33%)
- Fluid-fluid levels
- Bone erosion (20%)





Courtesy of Tudor Hughes, M.D.

Synovial Sarcoma



Summary

I. Soft Tissue Anatomy

- Compartmental

I. Imaging Work-Up

- Post-Treatment Imaging

II. Soft Tissue Tumors—MR Features

- WHO Classification

Thank You!

References

1. Anderson MW, Temple HT, Dussault RG, Kaplan PA. *Compartmental Anatomy: Relevance to Staging and Biopsy of Musculoskeletal Tumors*. AJR 1999; 173: 1663-1671.
2. Kransdorf MJ, Murphey MD. *Radiologic Evaluation of Soft Tissue Masses: A Current Perspective*. AJR 2000; 175: 575-587.
3. Kransdorf MJ, Murphey MD. Soft Tissue Tumors: Post-Treatment Imaging. *Radiologic Clinics of North America* 2006; 44:463-472.
4. Garner HW, Kransdorf MJ, Bancroft LW, Peterson JJ, Berquist TH, Murphey MD. Benign and Malignant Soft Tissue Tumors: Post Treatment MR Imaging. *Radiographics* 2009; 29:119-134.
5. Van Herendael BH, et al. *The Value of Magnetic Resonance Imaging in the Differentiation Between Malignant Peripheral Nerve Sheath Tumors and Non-Neurogenic Malignant Soft Tissue Tumors*. *Skeletal Radiology* 2006; 35: 745-753.
6. Bredella MA, et al. *Value of PET in the Assessment of Patients with Neurofibromatosis Type 1*. AJR 2007; 189: 928-935.
7. Vilanova JC, et al. *Soft tissue Tumors Update: MR Imaging Features According to the WHO Classification*. *European Radiology* 2007; 17: 125-138.
8. Blacksin MF, et al. *Superficial Soft Tissue Masses of the Extremities*. *Radiographics* 2006; 26:1289-1304.
9. Van Vliet M, et al. *Soft Tissue Sarcomas at a Glance: Clinical, Histological, and MR Imaging Features of Malignant Extremity Soft Tissue Tumors*. *European Radiology* 2009; DOI 10.1007.
10. Fayad L, et al. *Vascular Malformations in the Extremities: Emphasis on MR Imaging Features that Guide Treatment Options*. *Skeletal Radiology* 2006; 35:127-137.

References

11. Olson KI, et al. *Soft Tissue Cavernous Hemangioma*. Radiographics 2004; 24: 849-854.
12. Dinauer PA, et al. *Pathologic and MR Imaging Features of Benign Fibrous Soft Tissue Tumors in Adults*. Radiographics 2007; 27: 173-187.
13. Bancroft LW, Kransdorf MJ, Peterson JJ, O'Connor MI. *Benign Fatty Tumors: Classification, Clinical Course, Imaging Appearance, and Treatment*. Skeletal Radiology 2006; 36: 719-733.
14. Murphey MD, et al. *Benign Musculoskeletal Lipomatous Lesions*. Radiographics 2004; 24: 1433-1466.
15. Murphey MD, et al. *Imaging of Musculoskeletal Liposarcoma with Radiologic-Pathologic Correlation*. Radiographics 2005; 25: 1371-1395.
16. Bancroft LW, Peterson JJ, Kransdorf MJ. *MR Imaging of Tumors and Tumor-Like Lesions of the Hip*. Magnetic Resonance Imaging Clinics of North America 2005; 13:757-774.
17. Stacy GS, et al. *Pitfalls in MR Image Interpretation Prompting Referrals to an Orthopedic Oncology Clinic*. Radiographics 2007; 27:805-828
18. Kotilingam D, et al. *Staging Soft Tissue Sarcoma: Evolution and Change*. CA Cancer Journal for Clinicians 2006; 56: 282-291.
19. Clark MA, et al. *Soft Tissue Sarcomas in Adults*. The New England Journal of Medicine 2005; 353:701-711.
20. Bancroft LW, et al. *Soft Tissue Tumors of the Lower Extremities*. Radiologic Clinics of North America 2002; 40: 991-1011.
21. Beaman FD, et al. *Superficial Soft Tissue Masses: Analysis, Diagnosis, and Differential Considerations*. Radiographics 2007; 27: 509-523.